Home > Newsletters > RxTrials Institute Drug Pipeline Alert > Akorn-Strides Gets FDA Approval for Flumazenil Injection
RxTrials Institute Drug Pipeline Alert
May 21, 2008 | Vol. 6 No. 21
Akorn-Strides Gets FDA Approval for Flumazenil Injection
Akorn-Strides received an ANDA approval for Flumazenil Injection, packaged in 5-mL and 10-mL multiple-dose vials.
Flumazenil Injection is indicated for the complete or partial reversal of the sedative effects of benzodiazepines. Recent data estimate an annual market size of approximately $14 million.
Akorn-Strides is a joint venture that was formed in 2005 by Akorn and Strides Arcolab.
Novo Nordisk Gearing Up to Double Down on Diabetes Drugs in 2013Possible FDA Approval of New Pain Drug Using Other Drug’s Data May Save Struggling NeurogesXDrug-Diagnostic Sponsors Must Educate Sites to Avoid Bias That Can Kill ApprovalPfizer Hopes Pipeline Will Overflow Soon, With Five Potential New Products This Year
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.